Fact-checked by Dr. J. Adam, MD on . See our fact-checking policy.
Mass-market consumer brand with broad GLP-1 access — mature platform, competitive pricing, less clinical specialization
Confirm current monthly cost, dose-based increases, shipping, labs, and cancellation terms before enrollment.
Verify who reviews the intake, how follow-ups work, and what support is available for side effects.
For compounded medications, verify pharmacy type, formulation, state eligibility, and quality disclosures.
Compounded GLP-1 medications are not FDA-approved. Eligibility, pricing, pharmacy, and medication availability may change and require clinician review.
Hims & Hers (Hims for short) is the largest direct-to-consumer telehealth platform in the U.S. by revenue and the most-recognized consumer brand in the GLP-1 telehealth category. The platform's scale advantages are real: best-in-category app and onboarding experience, a fast typical time-to-prescription window as represented in its public materials and user flow, and the operational maturity to deliver consistent shipping and patient support across broad U.S. coverage areas.
For mass-market patients who don't need specialist-grade clinical depth, Hims is a clean entry point. The platform offers brand-name Wegovy and Zepbound (with insurance navigation) as well as a compounded semaglutide pathway. Pricing on compounded sema starts at $145–$165/mo for early titration doses, which is competitive at entry but rises with dose.
Hims is built for mass-market consumer experience, not for the patient with complex metabolic history. The clinical bench is competent but not specialist-led — patients with multiple medications, prior weight-loss program failures, or significant comorbidities are better served at Form Health or NexLife. Pricing is tiered and rises with dose escalation; patients reaching maintenance dose will face higher monthly costs than at flat-rate competitors. Hims has faced regulatory scrutiny around compounded GLP-1 advertising claims in 2024–2025 and adjusted some of its marketing language as a result; patients should confirm the current compounded program scope and pricing structure at signup.
Hims is the right pick for patients who want a frictionless consumer experience and don't need clinical specialization. For flat-rate cash-pay, NexLife wins on price and pricing transparency. For specialist clinical care, Form wins.
Hims & Hers pricing ranges from $199–$299/mo. Starting price is $145/mo (compounded semaglutide); $186/mo (compounded tirzepatide). Flat-rate, dose-independent. Pricing details and any titration upcharges are described above in the pricing section.
Hims & Hers is an established telehealth program. Solid mass-market option. Strong app, weaker on clinical depth than physician-led peers. Always verify a provider's pharmacy partnerships, prescribing physician credentials, and state availability before signing up.
Most direct-to-consumer compounded GLP-1 programs do not accept insurance for the medication itself. If insurance coverage matters to you, see our insurance pathway providers (Mochi Health, Ro, Form Health) and our insurance hub.
Hims & Hers prescribes: Compounded semaglutide, Compounded liraglutide.
Hims & Hers is available in Reports broad U.S. availability.
Eligibility is determined by an intake questionnaire and clinical review. Generally, FDA-approved weight-loss criteria are BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, sleep apnea). Off-label compounded prescribing is at the discretion of the prescribing clinician.
Editorial note. By GLP Agonists Editorial · Last updated June 12, 2026. This review is editorially independent. See our methodology and editorial disclosure. Not medical advice — always consult a licensed clinician.